SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DECODE GENETICS-*DCGN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (255)10/9/2006 12:13:43 PM
From: kenhott   of 313
 
Thanks! I did get a chance to listen to the replay.

There had been some musing about speeding/waiting for DCG051 to get more even with DCG031 and then pick the best one to move forward. Given these early trials are biomarker trials, a phase 1/2a trial with DCG051 could be done fairly "quickly". Up to this point, the musings were mostly outside people talking to themselves. But now with the delay, I wanted to see if mgt would think about this approach given the delay and the time/money to complete the stalled phase 3. As far as out licensing 031, I don't think there will be an over abundance of interested parties. But I guess all you need is one.

Edit: Reply. No. Once you start a trial, you will piss off a lot of docs if you stop it in mid trial. And then follow with the 051 trials later? That would not be fun to pull off. But given the "problem", it is a good excuse to reevaluate if that's in the best interest of the company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News